drugset / Trial / NCT00650429

A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT00650429

Phase 4 Completed 28 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study was conducted to examine the efficacy and tolerability of ziprasidone intramuscular (IM), and to assess the effect of switching from IM to oral ziprasidone for the treatment of acute exacerbation of schizophrenia and schizoaffective disorder in a Latin American population.

Timeline

Start
2003-10
Primary completion
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule 40 mg Intramuscular
Subject Ziprasidone Small molecule 80 mg Intramuscular